Articles by The Uromigos
Drs. David McDermott and Meredith Regan discuss statistics in clinical trials and upcoming RCC presentations at ASCO 2023.
We chat with Christopher Sweeney about the upcoming ASCO 2023 conference and what presentations to look out for.
Professor Nick James discusses the success of the STAMPEDE trial on the use of abiraterone in patients with prostate cancer.
Dr. Meeks discusses expression-based subtypes for defining pathologic response to neoadjuvant ICIs in patients with MIBC.
We discuss new data in bladder cancer and more presented at the 2023 American Urological Association Annual Meeting.
An ODAC meeting determined that olaparib plus abiraterone for mCRPC should be restricted to patients with BRCA mutations.
Dr. Daniel Heng joins us to discuss IMDC classification for RCC and the treatment of patients with favorable risk disease.
Amar Kishan, MD, discusses his recent meta-analysis on the effects of concurrent neoadjuvant versus adjuvant sequencing.
The latest topics in urologic oncology are discussed at the 14th International Uro-Oncology Conference in Brazil.
Toni Choueiri, MD, and Brian Shuch, MD, discuss several studies on the use of belzutifan in patients with renal cancer.
Ursula Vogl, MD, discusses her research and career progression in the prostate and renal cell cancer fields.
Sia Daneshmand, MD, reviews 2 studies on the use of erdafitinib for the treatment of NMIBC, including the THOR-2 trial.
The Uromigos are joined by Kala Sridhar, MD, to discuss the PET MUSE study on the impact of PET imaging in MIUC.
Karine Tawagi, MD, from the University of Illinois, discusses her work in immune-related toxicities.
Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer research from the 2023 ASCO GU Symposium.
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
Matt Galsky, MD discusses updates for the CheckMate 274 Trial at the 2023 ASCO GU Cancers Symposium with The Uromigos.
Brian Shuch, MD, discusses the ZIRCON Phase III imaging study on identification and characterization abilities of TLX250-CDx.
Christian Kollmannsberger, MD, FRCPC, discusses his presentation on utilizing miR371 as a biomarker for germ cell tumors.
Neeraj Agarwal, MD, FASCO, describes positive data from the TALAPRO-2 study on talazoparib and enzalutamide for mCRPC.
670 Madison Ave.
Manalapan, NJ 07726